URGN — UroGen Pharma Ltd. Stock Price, Chart & AI Report

Positive Mar 13, 2026 • 12:00 UTC GlobeNewswire Inc. • Urogen Pharma Ltd.

UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence

A national survey of over 1,100 bladder cancer patients conducted by the Bladder Cancer Advocacy Network (BCAN) reveals that nearly 80% of patients report fear of recurrence, with rates exceeding 90% among those under 50. The report documents significant procedural burden, with many patients undergoing five or more cystoscopies. UroGen Pharma commended the findings, emphasizing the need for treatment approaches that consider long-term quality of life alongside tumor control.

URGN bladder cancer recurrence fear of recurrence cystoscopy non-muscle invasive bladder cancer patient survey quality of life

Sentiment note

UroGen is positioned favorably in the article as a company addressing unmet needs in bladder cancer treatment. The company's CMO emphasizes the importance of considering patient quality of life and emotional burden in treatment decisions, aligning with the survey's findings. The article mentions UroGen's approved products for bladder cancer and notes that ZUSDURI launch is on-track, indicating positive business momentum.

Neutral Mar 13, 2026 • 11:00 UTC GlobeNewswire Inc. • Bladder Cancer Advocacy Network (Bcan)

Bladder Cancer Patients Report Delayed Diagnosis and Gaps in Support

A comprehensive survey of over 1,100 bladder cancer patients reveals significant gaps in care despite advances in treatment. Key findings include diagnostic delays for women (45% initially misdiagnosed with UTIs), inadequate mental health support (41% never offered resources), and financial barriers affecting treatment decisions, particularly for younger patients.

JNJ URGN bladder cancer patient survey diagnosis delays mental health support financial barriers healthcare disparities

Sentiment note

Identified as a research partnership supporter, but the article does not discuss any specific products, market performance, or business outcomes.

Neutral Dec 26, 2025 • 18:19 UTC The Motley Fool • Jonathan Ponciano

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally

Wildcat Capital Management, the family office of late billionaire David Bonderman, completely exited its position in UroGen Pharma by selling 495,606 shares worth $6.79 million in Q3. Despite UroGen's impressive 113% one-year rally, the exit signals disciplined profit-taking rather than loss of confidence, as biotech winners often see valuation risk increase after strong rallies.

URGN biotech exit profit-taking family office UroGen Pharma stock rally capital recycling valuation risk

Sentiment note

While the stock has rallied 113% over the past year, the complete exit by a disciplined long-term investor suggests the easy gains may have been realized and valuation risk is increasing. The operational story remains intact with Jelmyto and pipeline products, but the exit signals caution about near-term upside potential.

Positive Dec 5, 2025 • 13:00 UTC GlobeNewswire Inc. • Urogen Pharma Ltd.

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma granted restricted stock units to 14 new employees to support commercialization of Jelmyto and ZUSDURI, with up to 32,500 ordinary shares issuable upon vesting over three years.

URGN biotech RSUs employee grants urothelial cancer mitomycin

Sentiment note

Company is expanding its workforce, granting stock units to new employees, indicating growth and potential optimism about future business prospects

Positive Nov 25, 2025 • 13:00 UTC GlobeNewswire Inc. • Urogen Pharma Ltd.

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

UroGen Pharma will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in a fireside chat format, discussing their innovative cancer treatment technologies.

URGN PIPR biotech cancer treatment urothelial cancer healthcare conference

Sentiment note

Company is presenting at a major healthcare conference, showcasing positive clinical trial results with a 77.8% complete response rate in Phase 3 UTOPIA trial, and receiving FDA agreement on NDA submission strategy

Positive Oct 2, 2025 • 12:00 UTC GlobeNewswire Inc. • Urogen Pharma Ltd.

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

UroGen Pharma published a comprehensive review highlighting the clinical efficacy of ZUSDURI, an FDA-approved treatment for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer, demonstrating high complete response rates and a manageable safety profile.

URGN bladder cancer ZUSDURI mitomycin clinical trials non-surgical treatment

Sentiment note

The article presents positive clinical data for their drug ZUSDURI, highlighting high complete response rates, durable disease response, and a manageable safety profile, which suggests potential commercial success and medical innovation

Negative Jul 21, 2025 • 23:39 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit

A class action lawsuit has been filed against UroGen Pharma regarding its UGN-102 drug application, alleging misleading statements about clinical study design and FDA approval risks. The stock price dropped significantly after FDA advisory committee voted against drug approval.

URGN class action lawsuit UGN-102 FDA clinical study drug approval

Sentiment note

FDA advisory committee rejected drug application due to study design issues, stock price dropped nearly 71% across two news events, and a class action lawsuit was filed alleging misleading statements about clinical trial and drug approval prospects

Negative Jul 19, 2025 • 14:58 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in UroGen Pharma (URGN) to Inquire About Their Rights in Class Action Lawsuit

A class action lawsuit has been filed against UroGen Pharma regarding its UGN-102 drug application, alleging misleading statements about clinical study design and FDA approval risks.

URGN class action lawsuit UGN-102 FDA clinical study drug application

Sentiment note

Stock price dropped nearly 26% and 45% after FDA raised concerns about clinical study design and ultimately voted against approving the UGN-102 drug application for non-muscle invasive bladder cancer treatment

Negative Jul 15, 2025 • 23:35 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Against UroGen Pharma Ltd. And Encourages Investors to Contact the Firm

A class action lawsuit has been filed against UroGen Pharma regarding its UGN-102 drug application, alleging misleading statements about clinical study design and FDA approval risks.

URGN class action lawsuit FDA drug application clinical study

Sentiment note

Stock price dropped nearly 26% and 45% after FDA raised concerns about clinical study design and the Oncologic Drugs Advisory Committee voted against approving the UGN-102 drug application

Negative Jul 12, 2025 • 19:01 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire, P.C. has filed class action lawsuits against Organon, UroGen, Red Cat, and Fortrea, alleging misleading statements and financial misrepresentations that negatively impacted investor interests.

OGN URGN RCAT FTRE class action securities investor rights financial disclosure

Sentiment note

FDA rejected drug application for UGN-102, causing stock to fall 26-45% due to study design concerns

Negative Jul 8, 2025 • 01:00 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire announced class action lawsuits against Reckitt, UroGen, Red Cat, and Fortrea for alleged misleading statements and financial misrepresentations during specified class periods.

URGN RCAT FTRE class action lawsuit securities investor rights

Sentiment note

FDA raised concerns about clinical study design, leading to stock price drop and potential drug application rejection

Negative Jul 1, 2025 • 01:00 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire, P.C. reminds investors of class action lawsuits filed against Reckitt, UroGen, Red Cat, and Fortrea, alleging misleading statements and financial misrepresentations.

RBGLY URGN RCAT FTRE class action securities litigation investor rights financial disclosure

Sentiment note

FDA rejected drug application due to inadequate clinical study design, causing significant stock price drop and potential business challenges